Ceapro Inc V.CZO

Chemicals Specialty Chemicals

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

TSXV:CZO - Post by User

Ceapro Inc

<< Previous

Bullboard Posts

Next >>

Post by prophetoffactzon Nov 11, 2022 10:45pm

253 Views

Post# 35093174

Mitacs funding

PGX-processed yeast beta-glucans as an inhalable immuno-therapeutic/-prophylactic for COVID-19-induced lung fibrosis

The long-term effects of COVID-19 on individual health remain to be elucidated, with numerous reports emerging of fibrotic changes in the lung beyond the acute phase of the disease. Considering the reported cases of COVID-19 worldwide, even a small percentage of these patients developing lung fibrosis can have detrimental consequences on our healthcare system. In this project, we seek to expand on preliminary results from an ongoing collaboration between the labs of Kjetil Ask and Todd Hoare at McMaster University and our industry partner Ceapro regarding the utility of yeast beta-glucan particles processed using Ceapro’s pressurized gas expanded liquids (PGX) technology for modulating the immune system and serving as an anti-fibrotic agent without any added drug. PGX processing both purifies and expands the raw yeast beta-glucan product to both remove components that can cause undesirable side-effects and reduce the density of the material to make the particles easier to inhale directly into the targeted lung tissue. To advance this promising technology to clinical trials, we aim to optimize the delivery of PGX-YBG to the lung and validate its performance for reducing lung fibrosis, both alone and loaded with an anti-inflammatory drug currently used for COVID-19 therapy.

Intern:

Safaa Naiel;Nate Dowdall;Spencer Revill

Faculty Supervisor:

Kjetil Ask;Todd Hoare;Martin Kolb

Province:

Ontario

University:

McMaster University

Partner:

Ceapro

Sector:

Manufacturing